ADA 2018

In part 2 of this Exclusive Interview, Paula Trief talks with Diabetes in Control Publisher Steve Freed about the importance of communication between partners who are living with an ongoing health condition such as diabetes.

In part 3 of this Exclusive Interview, Paula Trief talks with Diabetes in Control Publisher Steve Freed about the results of a couples intervention trial, the Diabetes Support Project.

In part 4 of this Exclusive Interview, Paula Trief talks with Diabetes in Control Publisher Steve Freed about the importance of education for the partner of a person with diabetes, among other things they can do to be of support.

In part 5, the conclusion of this Exclusive Interview, Paula Trief talks with Diabetes in Control Publisher Steve Freed about the necessity of including mental health care in overall diabetes care, but also the need to show insurance companies how mental health services can contribute.

Jeffrey Emmick MD, Ph.D is the vice president of product development at Eli Lilly and Company. Dr. Emmick has been with the organization for over 20 years in various roles. Currently, he is responsible for late-stage clinical development for the entire Lilly diabetes portfolio.

In this Exclusive Interview, Jeffrey Emmick talks with Diabetes in Control during the ADA 2018 convention about Lilly diabetes products in the pipeline.

In this Exclusive Interview, Jeffrey Emmick talks with Diabetes in Control Medical Editor Joy Pape (with a special appearance by Diabetes In Control Publisher Steve Freed) during the ADA 2018 convention in Orlando about Lilly's diabetes products in the pipeline.

In part 1 of this Exclusive Interview, Jeffrey Emmick talks with Diabetes in Control Medical Editor Joy Pape about various products Lilly has brought to market and new products in development.

In part 2 of this Exclusive Interview, Jeffrey Emmick talks with Diabetes in Control Medical Editor Joy Pape about the combination of GLP1s and SGLTs while Diabetes in Control Publisher Steve Freed makes a quick appearance to ask about the possible effects of their combined use.

Tim Dunn, Ph.D., is the director of Clinical and Computational Research and an Abbott Volwiler Research Fellow.  He also serves as Chair of the Scientific Research Review Committee for investigator-initiated studies. His major areas of expertise are clinical trial strategy and trial design and real-world data analysis.